Efficacy of a skin barrier repair cream (Dermalex Eczema/ Atopifin) in atopic dermatitis patients
- Conditions
- atopic dermatitis10014982
- Registration Number
- NL-OMON38502
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Clinically diagnosed atopic dermatitis
Mild to moderate atopic dermatitis
At least two symmetrical (i.e. left and right side of the body) skin sites with comparable atopic dermatitis severity
Age between 18 and 70 years
- Other skin disease other than AD.
- Use of antihistamines prior to (72 hours) the study and/or expected use during the study.
- Use of antibiotics prior to (4 weeks) the study and/or expected use during the study.
- Use of inflammation suppressing medicines (e.g. corticosteroids, NSAIDs) prior to (4 weeks) the study and/or expected use during the study
- Use of systemic suppressing drugs (e.g. prednisone, methothrexate) prior to (4 weeks) the study and/or expected use during the study
-Severe disorders within the last 6 months before study (e.g. cancer, acute cardiac or circularity disorders, HIV, infectious hepatitis)
- Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome parameter in this study is transepidermal water loss (TEWL)<br /><br>as an effect parameter for the skin barrier function<br /><br>Erythema (skin redness) for the extent of skin inflammation </p><br>
- Secondary Outcome Measures
Name Time Method <p>Change of severity of atopic dermatitis<br /><br>Skin hydration<br /><br>Change in itching<br /><br>The amount of used cream/ointments (per day and total)<br /><br>Experiences of the subjects on different ointments and effect on skin / eczema<br /><br>symptoms.</p><br>